Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

被引:4
|
作者
Boiko, Anastasiia S. [1 ]
Mednova, Irina A. [1 ]
Kornetova, Elena G. [1 ,2 ]
Goncharova, Anastasiia A. [1 ]
Semke, Arkadiy, V [1 ]
Bokhan, Nikolay A. [1 ,2 ]
Ivanova, Svetlana A. [1 ,2 ]
机构
[1] Russian Acad Sci, Mental Hlth Res Inst, Tomsk Natl Res Med Ctr, Aleutskaya Str 4, Tomsk 634014, Russia
[2] Siberian State Med Univ, Dept Psychiat Addictol & Psychotherapy, Moskovsky Tract 2, Tomsk 634050, Russia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 10期
基金
俄罗斯科学基金会;
关键词
schizophrenia; metabolic syndrome; antipsychotics; body mass index; insulin; leptin; ghrelin; LEPTIN; GHRELIN; COMPONENTS; RESISTANCE; OLANZAPINE; PEOPLE; ADULTS; MASS;
D O I
10.3390/jpm12101655
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Metabolic syndrome (MetS) is a common complication of schizophrenia that is quite exacerbated by long-term use of (atypical) antipsychotics. The mechanism of MetS has neuronal, neuroendocrine, and neuroimmunological components and shows some overlap with those of aspects of schizophrenia. We examined 195 patients with schizophrenia (90 with and 105 without MetS) for the association of serum levels of ghrelin, insulin, and leptin with metabolic abnormalities. Serum glucose levels and lipid profiles were routinely measured with colorimetric enzymatic methods and hormone levels with multiplex analyzers. Leptin levels were highly significantly increased (p < 0.001) in people with MetS (9.966 [5.882; 21.496] vs. 6.35 [2.005; 11.753], Me [Q1; Q3]) and ghrelin levels were actually significantly decreased (p = 0.045). Insulin levels did not differ significantly between those with and without MetS (p = 0.162). In Spearman's correlation analysis between the hormone levels, body characteristics, and biochemical parameters, significant correlations were seen somewhat more often in people without MetS than in those with MetS and also less often for ghrelin than for the other hormones. We conclude that evidence exists for a role in the development of MetS especially for leptin, but that less is supporting a role for ghrelin.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Antipsychotic-Induced Metabolic Syndrome: A Review
    Akinola, Pelumi Samuel
    Tardif, Isabelle
    Leclerc, Jacinthe
    METABOLIC SYNDROME AND RELATED DISORDERS, 2023, 21 (06) : 294 - 305
  • [2] Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia
    Scaini, Giselli
    Quevedo, Joao
    Velligan, Dawn
    Roberts, David L.
    Raventos, Henriette
    Walss-Bass, Consuelo
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (03) : 369 - 380
  • [3] Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
    Paderina, Diana Z.
    Boiko, Anastasiia S.
    Pozhidaev, Ivan V.
    Bocharova, Anna V.
    Mednova, Irina A.
    Fedorenko, Olga Yu.
    Kornetova, Elena G.
    Loonen, Anton J. M.
    Semke, Arkadiy V.
    Bokhan, Nikolay A.
    Ivanova, Svetlana A.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (03):
  • [4] Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome
    Khasanova, Aiperi K.
    Dobrodeeva, Vera S.
    Shnayder, Natalia A.
    Petrova, Marina M.
    Pronina, Elena A.
    Bochanova, Elena N.
    Lareva, Natalia, V
    Garganeeva, Natalia P.
    Smirnova, Daria A.
    Nasyrova, Regina F.
    METABOLITES, 2022, 12 (08)
  • [5] The 'boon and bane' of antipsychotic-induced metabolic syndrome
    Venkatasubramanian, G.
    ACTA PSYCHIATRICA SCANDINAVICA, 2009, 120 (06) : 500 - 501
  • [6] Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia
    Kuzman, Martina Rojnic
    Mueller, Daniel J.
    PHARMACOGENOMICS, 2012, 13 (08) : 843 - 846
  • [7] Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
    Singh, Raghunath
    Stogios, Nicolette
    Smith, Emily
    Lee, Jiwon
    Maksyutynsk, Kateryna
    Au, Emily
    Wright, David C.
    De Palma, Giada
    Graff-Guerrero, Ariel
    Gerretsen, Philip
    Muller, Daniel J.
    Remington, Gary
    Hahn, Margaret
    Agarwal, Sri Mahavir
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2022, 12
  • [8] Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome
    Paredes, R. Madelaine
    Quinones, Marlon
    Marballi, Ketan
    Gao, Xiaoli
    Valdez, Celina
    Ahuja, Seema S.
    Velligan, Dawn
    Walss-Bass, Consuelo
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (08) : 1139 - 1148
  • [9] HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis
    Ma, Xiaojie
    Maimaitirexiati, Tuerxun
    Zhang, Rong
    Gui, Xueping
    Zhang, Wenhui
    Xu, Guozheng
    Hu, Gang
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2014, 18 (04) : 229 - 242
  • [10] Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?
    Vasileva, Svetlina S.
    Tucker, Jack
    Siskind, Dan
    Eyles, Darryl
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (05) : 625 - 639